Harvard Bioscience (HBIO) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Oil slips but stays near six-month highs on Saudi attacks
Tweet
Share
E-mailGet Alerts HBIO Hot Sheet
Price: $8.23 --0%
Revenue Growth %: +6.1%
Financial Fact:
Interest expense: -142K
Today's EPS Names:
SICP, OMID, ELME, More
Revenue Growth %: +6.1%
Financial Fact:
Interest expense: -142K
Today's EPS Names:
SICP, OMID, ELME, More
Join SI Premium – FREE
Harvard Bioscience (NASDAQ: HBIO) reported Q4 EPS of $0.06, $0.01 better than the analyst estimate of $0.05. Revenue for the quarter came in at $24.6 million versus the consensus estimate of $24.15 million.
GUIDANCE:
Harvard Bioscience sees Q1 2025 revenue of $19-21 million.
For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sierra Bancorp (BSRR) Tops Q3 EPS by 27c
- MitoCareX Bio completes first AI drug-discovery screening stage
- Why Ed Yardeni says the best market entry points are still to come
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
